Log In
Print
BCIQ
Print
Print this Print this
 

Incruse Ellipta, Umeclidinium bromide (Encruse Ellipta)

Also known as: Incruse

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionLong-acting muscarinic antagonist (LAMA) delivered via the Ellipta inhaler
Molecular Target Muscarinic receptor
Mechanism of ActionMuscarinic receptor antagonist
Therapeutic ModalityMedical Devices: Drug/device combination
Latest Stage of DevelopmentMarketed
Standard IndicationChronic obstructive pulmonary disease (COPD)
Indication DetailsTreat chronic obstructive pulmonary disease (COPD)
Regulatory Designation U.S. - Undisclosed Review (Treat chronic obstructive pulmonary disease (COPD));
EU - Standard Review (Treat chronic obstructive pulmonary disease (COPD));
Japan - Standard Review (Treat chronic obstructive pulmonary disease (COPD))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today